Literature DB >> 17267620

Comparison of inhibition potentials of drugs against zidovudine glucuronidation in rat hepatocytes and liver microsomes.

Yuji Mano1, Takashi Usui, Hidetaka Kamimura.   

Abstract

Hepatocytes and liver microsomes are considered to be useful for investigating drug metabolism catalyzed mainly via glucuronidation. However, there have been few reports comparing the glucuronidation inhibition potentials of drug in hepatocytes to those in liver microsomes. 3'-Azido-3'-deoxythymidine (AZT, zidovudine) glucuronidation (AZTG) is the major metabolic pathway for AZT. In this study, the inhibition potentials of drugs against UDP-glucuronosyltransferase (UGT)-catalyzed AZTG in the hepatocytes and liver microsomes of rats are compared. The AZTG inhibition potentials of diclofenac, diflunisal, fluconazole, indomethacin, ketoprofen, mefenamic acid, naproxen, niflumic acid, and valproic acid in liver microsomes and hepatocytes were investigated using liquid chromatography with tandem mass spectrometry. Diflunisal (inhibition type: noncompetitive) inhibited AZTG most potently in rat liver microsomes (RLMs) with an IC(50) value of 34 microM. The IC(50) values of diclofenac, fluconazole, indomethacin, ketoprofen, mefenamic acid, naproxen, niflumic acid, and valproic acid against AZTG in RLMs ranged from 34 to 1791 microM. Diclofenac, diflunisal, indomethacin, ketoprofen, naproxen, and valproic acid inhibited AZTG in hepatocytes with IC(50) values of 58, 37, 88, 361, 486, and 281 microM, respectively. These values were similar to those obtained in RLMs. In conclusion, the AZT glucuronidation inhibition potentials of drugs in the hepatocytes and liver microsomes of rats were found to be similar, and liver microsomes can be useful for evaluating UGT isozyme inhibition potentials.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17267620     DOI: 10.1124/dmd.106.014225

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  4 in total

1.  Acute liver failure enhances oral plasma exposure of zidovudine in rats by downregulation of hepatic UGT2B7 and intestinal P-gp.

Authors:  Fan Wang; Ming-Xing Miao; Bin-Bin Sun; Zhong-Jian Wang; Xian-Ge Tang; Yang Chen; Kai-Jing Zhao; Xiao-Dong Liu; Li Liu
Journal:  Acta Pharmacol Sin       Date:  2017-08-03       Impact factor: 6.150

2.  Novel in vitro-in vivo extrapolation (IVIVE) method to predict hepatic organ clearance in rat.

Authors:  Ken-ichi Umehara; Gian Camenisch
Journal:  Pharm Res       Date:  2011-10-20       Impact factor: 4.200

Review 3.  Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook.

Authors:  John F Deeken; Liron Pantanowitz; Bruce J Dezube
Journal:  Curr Opin Oncol       Date:  2009-09       Impact factor: 3.645

4.  Humanized UGT2 and CYP3A transchromosomic rats for improved prediction of human drug metabolism.

Authors:  Yasuhiro Kazuki; Kaoru Kobayashi; Masumi Hirabayashi; Satoshi Abe; Naoyo Kajitani; Kanako Kazuki; Shoko Takehara; Masato Takiguchi; Daisuke Satoh; Jiro Kuze; Tetsushi Sakuma; Takehito Kaneko; Tomoji Mashimo; Minori Osamura; Mari Hashimoto; Riko Wakatsuki; Rika Hirashima; Ryoichi Fujiwara; Tsuneo Deguchi; Atsushi Kurihara; Yasuko Tsukazaki; Naoto Senda; Takashi Yamamoto; Nico Scheer; Mitsuo Oshimura
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-04       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.